CRO Emmes buys visual-exam-focused Clinical Edge

2022-09-28

并购

CRO Emmes buys visual-exam-focused Clinical Edge

Preview

来源: FierceBiotech

Emmes made its fifth acquisition in under two years by snapping up Clinical Edge for an undisclosed price, giving the CRO a dominant position in the ophthalmology certification arena.

Emmes has snapped up Clinical Edge for an undisclosed price, extending the Maryland-based CRO’s string of acquisitions to five in just under two years.

Clinical Edge is known for its training and certification of visual function examiners at investigator sites conducting ophthalmic clinical trials. The pairing with Emmes’ Optym ophthalmology certification unit puts the CRO at the head of the pack in such services, the company said in a Sept. 28 release.

With the deal, the company now boasts a base of 36 ophthalmic certifiers, most of whom are doctors of optometry or medicine. Financial terms of the deal weren’t disclosed.

Emmes moved quickly to rebrand the unit as OptymEdge just ahead of this year’s annual meeting of the American Academy of Ophthalmology that kicks off Friday in Chicago.

“This acquisition makes us a powerhouse in the ophthalmology training and certification area, a critical part of determining the safety and efficacy of new treatments for eye disease,” Emmes CEO Christine Dingivan, M.D., said in the release. “This is another positive step in our growth and globalization effort.”

Emmes has been on a global spending spree in recent years, buying Plymouth, Massachusetts-based rare disease trials contractor Casimir in March for an undisclosed price. It followed the acquisition of U.K.-based rare disease specialist Orphan Reach and German late-phase study-focused contractor Institut Dr. Schauerte last year along with Czech Republic-headquartered Neox in December 2020.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构